Subject Matter Experts
Carrie D’Andrea is a skilled clinical operations executive with over 20 years of experience. She began her career as a Clinical Research Associate and has assumed positions of increasing responsibility. Her most recent position was the Vice President of Clinical Operations at Edge Therapeutics, where she was responsible for the strategy and execution of phase 1-4 studies.
Carrie has worked in small to large pharmaceutical companies in numerous therapeutic areas, where she has led the following activities: protocol development, all aspects of study conduct, vendor identification/selection, resource planning, study and department budgets. She has managed in-house clinical trial managers and clinical scientists and was responsible for CRO oversight. Carrie’s expertise also includes continuous improvement in GCP activities and building department infrastructure through the implementation of SOPs and working practices.
She received her Master’s Degree in Pharmaceutical Quality and Regulatory Affairs from Temple University. Carrie teaches “Practical Aspects of Clinical Research Design and Conduct” at Rutgers University and was named a Healthcare Business Women’s Association Rising Star in 2009.
Mark Devlin is a senior commercial leader in the biopharmaceutical arena who drives revenue growth. He is highly skilled in designing pricing and contracting strategies that deliver unfettered portfolio market access with Commercial and Government payors. His proficiency spans all payor channels and he has a track record of success in sales, marketing and market access across a diverse set of therapeutic areas.
Mark most recently was Senior Vice President, Managed Markets at Allergan PLC, a global pharmaceutical company with revenues of approximately $16B. He led a team of 130 people, served on executive steering committees and reported directly to the Chief Commercial Officer. In this role Mark led the portfolio pricing and market access strategies for a $12B U.S. pharmaceutical portfolio of approximately 40 brands in seven therapeutic markets. In addition to market access, Mark was responsible for Trade sales, distribution and customer service with all wholesale and retail customers. He managed the largest portfolio of contracted products on major PBM and health plan formularies and achieved a brand portfolio average of over 73% unrestricted access at discount rates below industry average. He also created and led a $500M annual patient co-pay support program for over three dozen brands that resulted in a Rx fulfillment rate over 82% and surpassing industry average. At the end of 2017, he negotiated new wholesaler distribution agreements that will save Allergan $60M over three years through fee reductions at all major U.S. drug wholesalers.
From 2007 – 2014, Mark was Senior Vice President, Managed Markets, Government and Policy at Forest Laboratories, where he developed corporate strategy and messaging on health care and public policy issues and led a team of 85 professionals in account management, contract operations, channel marketing, government affairs and public policy. In this role he launched a series of highly successful products, including Namenda XR in the commercial, Medicare and long-term care markets, and Bystolic, a branded beta-blocker in a heavily generic cardiovascular market. He also successfully managed the company’s federal lobbying initiative in support of the 2012 GAIN Act which resulted in an extra 5 years of market exclusivity for the company’s lead anti-infective product.
From 2002 – 2007, he was Vice President, Sales/Operations, where he spearheaded many successful product launches, co-led enterprise-wide technology deployments and designed multiple sales force incentive compensation programs. He also served on a corporate steering committee with co-promotion partner Sankyo Pharmaceuticals and was a founding member of the Forest Corporate Compliance Committee. Earlier in his career (1986 – 2002), Mark advanced through a series of increasingly responsible sales and operations roles in New England and New York.
Mark earned a Bachelor of Science in Biology with a minor in Chemistry at Fairleigh Dickinson University and attended the F.W. Olin Graduate School of Business at Babson College. He has continued his professional development with programs in strategic negotiation, executive leadership, group dynamics and other subjects through programs at Harvard University, Columbia University and the American Management Association.
Mary Anne Greenberg
For over 20 years, first as owner of Alliance Healthcare, a successful licensed healthcare staffed call center and in more recent years, as Ashfield’s President of North America, has served pharmaceutical executives by providing the industry the gold standard in services both in strategy and tactics.
A passion for patients as well as a philosophy of ‘do the right thing’ underscored the management and growth of businesses in her portfolio including medical Information, payer and market access, field and inside commercial sales, field and phone patient support and pharmacovigilance in US and Canada.
Mary Anne provides a unique prospective to evaluating and executing outsourced services. Mary Anne is active in her community fund raising for local charities and service as an executive board member in a local political organization.
Mary Anne lives in downtown Princeton with her husband.
John P. Hall is a clinical development executive with 15+ years of industry experience. He began his career with a niche clinical research organization working through various operational departments before transitioning to the U.S. subsidiary of a Japanese pharmaceutical. He has been involved in all aspects of clinical trials from feasibility studies to archiving, Phase 1 (First in Human) to Phase 4 (Real World Evidence).
John started Shore Research & Development, LLC in 2012, a clinical operations consultancy focused on early clinical development. Shore R&D provides consultancy services for small to medium size biotechnology companies. Clients have been both private and public, primarily U.S. based but also included clients in South Korea and Belgium.
Over the past several years John has worked with clients to identify gaps in trial project management. John has successfully maximized the RFP process for trial services which has yielded costs savings and ensures vendor timeline accountability.
John is on the editorial board for Clinical Leader and on Gerson Lehrman Group Council of advisors. He received his BS from the University of Rhode Island and his MBA from Rider University. John is an avid runner and surfer and started Fund for 51 in 2011 to raise money for Duchenne Muscular Dystrophy.
John and his wife live in Spring Lake Heights, NJ and have 4 children.
Bill O’Donnell is an accomplished strategic, operational and financial executive with more than three decades of experience.
Over the past several years Bill teamed with a Private Equity Group and built a progressive healthcare communication company through a series of strategic acquisitions and integration of healthcare advertising, PR and digital companies. The company was built to serve clients across the healthcare ecosystem to include payers, providers, healthcare tech as well as drug and device manufactures.
Previously, Bill was the President and COO of inVentiv Health Communications. With over 2,000 employees, Bill led one of the largest healthcare communications companies worldwide. inVentiv worked with global pharma, biotech, medical device and diagnostic companies. inVentiv brought industry leading advertising, PR, medical education, digital, and media together for integrated solutions to accelerate performance for client’s brands.
Bill began his career in the banking industry in both financial and operational roles at Bank One, now JP Morgan Chase. Over his career, Bill forged long lasting relationships between his organizations and his clients built on trust, transparency and the attainment mutual of goals.
Bill and his wife live in Columbus, OH and have 4 children.
Ken Taylor is an accomplished agency executive with more than 25 years of success across the media, advertising and healthcare technology industries. Ken spent seven years as President at leading media agency, Starcom Worldwide. Most recently, Ken was a Managing Director at health tech start-up, Outcome Health.
Ken has partnered with numerous Fortune 500 companies as well as emerging brands to lead and transform their media practices. He has worked with the country’s largest and most successful marketers in developing media capabilities and building marketplace partnerships.
Through his extensive background in media, he has a depth of experience in areas critical to today’s marketers including media strategy, consumer behavior, digital transformation, data, analytics and investment stewardship.
Ken lives in Elmhurst, IL with his wife and two children.